Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743121 | 0.81 | CYP1A2 (0.41) | CYP3A4TSHRSMN1; SMN2DPP4ALDH1A1 | |
| SCHEMBL10202117 | 0.78 | MAPK1 (0.32) | IDO1ALDH1A1 | |
| SCHEMBL4740888 | 0.77 | ALDH1A1 (0.40) | CYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4742148 | 0.77 | ALDH1A1 (0.44) | CYP3A4TSHRSMN1; SMN2DPP4ALDH1A1 | |
| SCHEMBL4730696 | 0.77 | IDO1 (0.32) | IDO1 | |
| SCHEMBL18923012 | 0.76 | DPP4 (0.32) | TSHRDPP4ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16980481 | 0.74 | GRIN2B (0.46) | TSHRSMN1; SMN2 | |
| SCHEMBL18923114 | 0.74 | GRIN2B (0.46) | TSHRSMN1; SMN2 | |
| SCHEMBL16563021 | 0.72 | DPP4 (0.35) | CYP3A4TSHRDPP4 | |
| SCHEMBL4743137 | 0.72 | DPP4 (0.35) | CYP3A4TSHRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | IDO1 1090/4885CYP3A4 375/4885TSHR 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.